openPR Logo
Press release

Gaucher Disease Market Analysis, Manufacturing Cost Structure, Growth Opportunities And Restraint To 2022

06-14-2017 09:35 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from:

Gaucher Disease Market Analysis, Manufacturing Cost

A Brief about Gaucher Disease

About Gaucher Disease

Gaucher disease is a genetic disorder which is related to metabolism. In this disorder, body fails to make or not make enough glucocerebrosidase, it is a type of enzyme which is necessary to breakdown and recycle a type of fat i.e.,Glucocerebroside. Thiscauseto build up layers of glucocerebroside in liver, bone marrow, spleen and nervous system. These layers interrupt the normal working of these organs.

Request A Sample:

Market analysis

Gaucher disease is inherited. There are approximately 6000 individuals with gaucher disease in United States, men and women in equal number.The therapies for this disease are available in market. Thesales of therapeutics for gaucher disease were about $875 million in 2014. It is expected that, the sales will rise to $1.16 billion by 2022 across the 7 major markets of UK, US, Italy, Israel, Germany, Spain and France, at the compound annual growth rate of 2.9%. So the North America Gaucher disease market is expected to grow on steady rate of 2.9%. Interestingly, the country which will experience highest growth is Israel with compound annual growth rate of 8.4%. This growth will be driven by increase in rate of diagnostic rate due to high level of disease awareness in Israel.

Signs and symptoms

Gaucher disease is classified into three types, according to the absence, presence and extent of the neurological involvement.

Type 1-Nonneuronopathic Gaucher disease
Type 2- Acute nonneuronopathic Gaucher disease
Type3- Chronic nonneuronopathic Gaucher disease
Type 1 is most common and least severe case of gaucher disease. In this symptoms like anemia, enlarged liver or spleen are common. Skeletal weakness and bone diseases may be extensive. The brain and nervous system are not affected, but lung and kidney impairment may occur.

Type 2 Symptoms begin with 6 months within birth which includes enlarged liver and spleen, poor ability to suck and swallow extensive and progressive brain damage and eye movement disorders. Usually children with this disease die within age of 2.

Type 3 symptoms may start any time during childhood or adulthood. It is slowly progressive but milder as compare to type 2. The symptoms include skeletal irregularities, poor coordination, enlarged liver and spleen, eye movement disorder and anemia.

The diagnosis isconfirmed through DNA analysis and enzyme testing in laboratory.


The treatments available for type1 and type3 are –

Enzyme Replacement Therapy(ERT)
Substrate Reduction Therapy(SRT)
Enzyme Replacement Therapy balances the low levels of glucocerebrosidase enzyme with modified version of normal human enzyme. This helps to breakdown the fat accumulated near organs.

Substrate Reduction Therapy works differently than Enzyme Replacement Therapy. Instead of balancing the low level of glucocerebrosidase enzyme, it reduces the glucocerebroside in the body. This reduces the work of body’s enzyme to break and degrade fat i.e. glucocerebroside. SRT is oral medications.

According to the National Gaucher foundation from United States, the incidence of gaucher disease is about one in 20,000 live births.

Read More:

About Us:
QY Research Groups is a company that simplifies how analysts and decision makers get industry data for their business. Our unique colossal technology has been developed to offer refined search capabilities designed to exploit the long tail of free market research whilst eliminating irrelevant results. QY Research Groups is the collection of market intelligence products and services on the Web. We offer reports and update our collection daily to provide you with instant online access to the world's most complete and current database of expert insights on Global industries, companies, products, and trends.

Contact us:
Follow Us:
LinkedIn | Twitter| Facebook

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Gaucher Disease Market Analysis, Manufacturing Cost Structure, Growth Opportunities And Restraint To 2022 here

News-ID: 577665 • Views: 150

More Releases from

Digital Advertising Market Analysis, Market Size, Application Analysis, Regional …
A Global Emergence of New Aged Digital Advertising What does that mean to us? There has been a major increase in the number of start-ups across the globe today. People have well thought out ideas, the sense of doing perfect business, maintaining their ethics and being very accurate and spectacular entrepreneurs. Innovation has taken yet another turn and has worked out in everyone’s favour, especially since the kinds of ideas that have
Latest Report On Magnetic Resonance Imaging (MRI) Systems Market, Forecast To 20 …
Magnetic resonance imaging is a radiological non invasive medical imaging technique by which the anatomy and physiology of different organs of the body is captured. The device was invented by Paul C. Lauterbur in September of 1971. It differs from CT scan by the fact that it does not use x-rays. Hence it is safer, but it takes longer time that CT scan is louder and people with implants such
Latest Market Analysis On Neuroendovascular Coil Market, Top Manufacturers Are S …
Endovascular coiling is a procedure is performed to hinder the flow of blood into an aneurysm which is a weakened area in the wall of an artery. Recently, this method is more frequently used in treating brain aneurysms and the process if termed as Neuroendovascular Coil or aneurysm coil embolization. The coiling method was first introduced in the 1990s as a way of treating ruptured or unruptured aneurysms without the
Orthopedic Surgical Robots Market - Global Trends, Market Share, Industry Size, …
Robotic Surgery is a breakthrough in the field of medical science, aiming to improve the accuracy and precision of surgical procedures. In case of orthopaedics, robots are mainly focused on increasing the precision of preparing bony surfaces, which cannot, otherwise, be achieved by human surgeons. Robots were first used for hip replacement and on successful execution of it, it was also used for knee arthroplasty. It has been observed that

All 5 Releases

More Releases for Gaucher

Gaucher Disease Market Development Trends, Competitive Landscape and Key Regions
Gaucher Disease Market is a Professional and in-depth market research on the current state of the Global Gaucher Disease. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Gaucher Disease Market analysis is provided for the international market including development history, competitive landscape analysis, and by major regions development status (Asia-Pacific, North America, Europe, Middle East & Africa), and other regions
Gaucher Disease Market Pharmaceuticals & Healthcare Analysis 2018 to 2025
In 2017, the global Gaucher Disease market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2018-2025. Companies Mentioned are: Sanofi, Shire, Actelion Pharma, Pfizer, ISU Pharm, .... Sample/Inquiry at: Further, the market is segmented based on the applications, types and Geography area such as  Gaucher Disease Market, by Types: Enzyme Replacement Therapy Substrate Reduction Therapy Gaucher Disease Market, by Applications: Non-Neuronopathic Gaucher Disease Neuronopathic Gaucher Disease Geographically,
Gaucher Disease Treatment Market, by Disease Type, Therapy Type
Gaucher disease is an autosomal recessive inherited metabolism disorder where a type of fat (lipid) called glucocerebroside is unable to degrade. Body synthesis enzyme called glucocerebrosidase, which breakdowns and reprocesses glucocerebroside. Gaucher disease is caused by mutations of a single gene called GBA, which leads to very low levels of glucocerebrosidase enzyme leading to low degradation of glucocerebroside. There are three types of Gaucher disease namely: type 1, type 2,
Global Gaucher Disease Market Trends, Analysis, Players & Forecast by 2025
An up-to-date research report has been disclosed by Market Research Hub highlighting the title “Global Gaucher Disease Market Research Report 2018” which provides an outlook of current market growth as well as the expected forecast including Rate on Investment (ROI) together with growing CAGR near XX% during 2018-2025. The report studies gate drivers in global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue,
United States Gaucher Disease Market Report 2017
In this report, the United States Gaucher Disease market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: The West Southwest The Middle Atlantic New England The South The Midwest with sales (volume), revenue (value), market share and growth rate of Gaucher Disease in these
Gaucher Disease Market 2017 - Sanofi, Shire, Actelion Pharma, Pfizer
Apex Research, recently published a detailed market research study focused on the "Gaucher Disease Market" across the global, regional and country level. The report provides 360° analysis of "Gaucher Disease Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Gaucher Disease industry, and estimates the future trend of Gaucher Disease market on